ENGN Earnings enGene Therapeutics Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–15 of 15
| Q2 2026 | 2026-04-30 | -0.88 | 2026-06-15 | 10-Q |
| Q1 2026 | 2026-01-31 | 0.44 | 2026-03-09 | 10-Q |
| FY 2025 | 2025-10-31 | 2.29 | 2025-12-22 | 10-K |
| Q3 2025 | 2025-07-31 | 1.56 | 2025-09-11 | 10-Q |
| Q2 2026 | 2025-04-30 | -0.99 | 2026-06-15 | 10-Q |
| Q1 2026 | 2025-01-31 | 0.48 | 2026-03-09 | 10-Q |
| FY 2025 | 2024-10-31 | 1.46 | 2025-12-22 | 10-K |
| Q3 2025 | 2024-07-31 | 1.12 | 2025-09-11 | 10-Q |
| Q2 2025 | 2024-04-30 | 0.82 | 2025-06-12 | 10-Q |
| Q1 2025 | 2024-01-31 | 0.46 | 2025-03-10 | 10-Q |
| FY 2024 | 2023-10-31 | 151.22 | 2024-12-19 | 10-K |
| Q3 2024 | 2023-07-31 | 30.77 | 2024-09-10 | 10-Q |
| Q2 2024 | 2023-04-30 | 22.19 | 2024-06-14 | 10-Q |
| Q1 2024 | 2023-01-31 | 13.29 | 2024-03-11 | 10-Q |
| FY 2023 | 2022-10-31 | 44.30 | 2024-01-29 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.